EMA Authorised: Jardiance (empagliflozin) — Boehringer Ingelheim International GmbH

View source ↗

Summary

EMA authorised Jardiance (empagliflozin) in the European Union for type 2 diabetes mellitus, heart failure, and chronic kidney disease, under Boehringer Ingelhe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Heart Failure
• Type 2 Diabetes Mellitus

Drugs mentioned

• Jardiance (empagliflozin)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus, Type 2;Heart Failure;Renal Insufficiency, Chronic. MAH: Boehringer Ingelheim International GmbH. Decision date: 24/03/2026